Recursion Pharmaceuticals, Inc.
RXRX Nasdaq
SEC CIK 1601830
Follow Recursion Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$18.6M
+258.5% vs same quarter last year
Net income
−$119M
+26.6% vs same quarter last year
EPS, diluted
−$0.22
+38.9% vs same quarter last year
Operating cash flow
−$77.4M
+34% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $74.7M | −$644.8M |
| FY24 | $58.8M | −$463.7M |
| FY23 | $44.6M | −$328.1M |
| FY22 | $39.8M | −$239.5M |
| FY21 | $10.2M | −$186.5M |
| FY20 | $4M | −$87M |
| FY19 | $2.3M | −$61.9M |
| FY18 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 5% | −867.9% | −863.4% |
| FY24 | 23.1% | −814.1% | −788% |
| FY23 | 4.5% | −785.3% | −736% |
| FY22 | −21.2% | −616.7% | −601% |
| FY21 | 100% | −1795.8% | −1832.2% |
| FY20 | 100% | −2135.7% | −2196% |
| FY19 | - | −2692.6% | −2668.3% |
| FY18 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$378.3M |
| FY24 | −$372.9M |
| FY23 | −$299.7M |
| FY22 | −$120.6M |
| FY21 | −$198.4M |
| FY20 | −$51.2M |
| FY19 | −$61M |
| FY18 | - |
- Recursion Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Recursion Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | −863.4% | −30.6% |
| FY24 | −788% | −47% |
| FY23 | −736% | −58% |
| FY22 | −601% | −80.4% |
| FY21 | −1832.2% | −71.8% |
| FY20 | −2196% | −62.2% |
| FY19 | −2668.3% | −46.2% |
| FY18 | - | −49.6% |